Oppenheimer Weighs in on Avenue Therapeutics Inc’s Q1 2019 Earnings (ATXI)
Avenue Therapeutics Inc (NASDAQ:ATXI) – Equities researchers at Oppenheimer raised their Q1 2019 earnings estimates for shares of Avenue Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. Oppenheimer analyst L. Gershell now anticipates that the company will earn ($0.46) per share for the quarter, up from their previous forecast of ($0.53). Oppenheimer also issued estimates for Avenue Therapeutics’ Q2 2019 earnings at ($0.65) EPS and FY2019 earnings at ($1.54) EPS.
Separately, ValuEngine upgraded shares of Avenue Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th.
Several hedge funds have recently added to or reduced their stakes in the company. National Asset Management Inc. raised its holdings in shares of Avenue Therapeutics by 4.7% during the fourth quarter. National Asset Management Inc. now owns 66,250 shares of the company’s stock valued at $358,000 after acquiring an additional 3,000 shares during the period. Northern Trust Corp acquired a new stake in shares of Avenue Therapeutics during the fourth quarter valued at approximately $79,000. Finally, Opaleye Management Inc. acquired a new stake in shares of Avenue Therapeutics during the fourth quarter valued at approximately $2,678,000. Institutional investors and hedge funds own 6.46% of the company’s stock.
In other news, Director Neil Herskowitz purchased 5,000 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were acquired at an average price of $5.46 per share, for a total transaction of $27,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought 15,947 shares of company stock worth $91,630 in the last 90 days. 5.00% of the stock is owned by company insiders.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Further Reading: How to use beta for portfolio diversification
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.